JRCT ID: jRCT2080221614
Registered date:12/10/2011
Basic Information
Recruitment status | |
---|---|
Health condition(s) or Problem(s) studied | psoriasis |
Date of first enrollment | 12/10/2011 |
Target sample size | |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : AIN457 INN of investigational material : Secukinumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Subcutaneous Injection |
Outcome(s)
Primary Outcome | PASI 75 |
---|---|
Secondary Outcome | PASI 50/75/90/100, IGA |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Moderate and severe plaque-type psoriasis diagnosed for at least 6 months. |
Exclude criteria | -Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). -Current drug-induced psoriasis. -Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor. |
Related Information
Primary Sponsor | Novartis Pharma K.K. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | JapicCTI-111655 |
Contact
Public contact | |
Name | |
Address | 0120-003-293 |
Telephone | |
Affiliation | Novartis Pharma K.K. |
Scientific contact | |
Name | |
Address | |
Telephone | |
Affiliation |